<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7706726</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2822</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">Clin Ther</journal-id>
<journal-title-group>
<journal-title>Clinical therapeutics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0149-2918</issn>
<issn pub-type="epub">1879-114X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28129947</article-id>
<article-id pub-id-type="pmc">5344195</article-id>
<article-id pub-id-type="doi">10.1016/j.clinthera.2016.12.014</article-id>
<article-id pub-id-type="manuscript">NIHMS840624</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Target intestinal microbiota to alleviate disease progression in amyotrophic
lateral sclerosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Yong-guo</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Shaoping</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yi</surname>
<given-names>Jianxun</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xia</surname>
<given-names>Yinglin</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jin</surname>
<given-names>Dapeng</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Jingsong</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Jun</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Division of Gastroenterology and Hepatology, Department of
Medicine University of Illinois at Chicago, Chicago, IL, USA</aff>
<aff id="A2"><label>2</label>Department of Biochemistry, Rush University Medical Center,
Chicago, IL, USA</aff>
<aff id="A3"><label>3</label>Department of Physiology, Kansas City University of Medicine and
Bioscience, Kansas City, MO, USA</aff>
<author-notes>
<corresp id="cor1"><bold>Corresponding Author</bold>, Jun Sun, PhD, AGAF, Associate
Professor, Division of Gastroenterology and Hepatology, Medicine, University of Illinois
at Chicago, 840 S Wood Street, Room 704 CSB, MC716, Chicago, IL, 60612, Tel: 312-996-5020;
<email>junsun7@uic.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P41">
<bold>Conflicts of interests:</bold>
</p>
<p id="P42">The authors have indicated that they have no other conflicts of interest
regarding the content of this article.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>6</day>
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>2</month>
<year>2018</year>
</pub-date>
<volume>39</volume>
<issue>2</issue>
<fpage>322</fpage>
<lpage>336</lpage>
<!--elocation-id from pubmed: 10.1016/j.clinthera.2016.12.014-->
<abstract>
<sec id="S1">
<title>Purpose</title>
<p id="P1">Emerging evidence has demonstrated that gut microbiome plays essential roles in
the pathogenesis of human diseases in distant organs. Amyotrophic lateral sclerosis
(ALS) is a fatal neurodegenerative disease characterized by progressive loss of motor
neurons. Treatment with the only FDA approved drug, Riluzole, extends patient life span
only for a few months. Thus, there is an urgent need to develop novel interventions for
alleviating the disease progression and improving the quality of life for ALS patients.
Here we present evidence that intestinal dysfunction and dysbiosis may actively
contribute to ALS pathophysiology.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P2">We used G93A transgenic mice as a model of human ALS. The G93A mice show
abnormal intestinal microbiome and damaged tight junctions, which occur before ALS
disease onset. Feeding of the G93A mice with butyrate, a natural bacterial product.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P3">Feeding of the G93A mice with butyrate, restores the intestinal microbial
homeostasis, improves the gut integrity, and prolongs the life span of the ALS mice.
Paneth cells are specialized intestinal epithelial cells that regulate the
host-bacterial interactions. At the cellular level, we show that abnormal Paneth cells
were significantly decreased in the ALS mice treated by butyrate. Butyrate treatment
decreases aggregation of the G93A-SOD1 mutated protein in both ALS mice and cultured
human intestinal epithelial cells.</p>
</sec>
<sec id="S4">
<title>Implications</title>
<p id="P4">Our study highlights the complex role of gut microbiome and intestinal
epithelium in the progression of ALS and presents butyrate as a potential therapeutic
reagent to restore ALS dysbiosis.</p>
</sec>
</abstract>
<kwd-group>
<kwd>ALS</kwd>
<kwd>butyrate</kwd>
<kwd>dysbiosis</kwd>
<kwd>intestinal permeability</kwd>
<kwd>microbiome</kwd>
<kwd>tight junctions</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>